New Data Show Genentech’s Enspryng Significantly Reduces Severity and Risk of Relapse in Neuromyelitis Optica Spectrum Disorder

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will present new Enspryng (satralizumab-mwge) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MSVirtual2020, the 8th Joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) – European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Meeting, in addition to longer-term efficacy data supporting the continued effect of Enspryng on reducing the risk of NMOSD relapse, as well as its favorable benefit:risk profile.

“The data for Enspryng at MSVirtual2020 are promising and suggest it significantly reduces relapse severity and frequency, which are important goals of the treatment for people with NMOSD,” said Anthony Traboulsee, M.D., neurologist and professor, University of British Columbia, and Research Chair of the MS

Read More

New data show Roche’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD)

  • ENSPRYNG lowered relapse severity in double-blind periods of SAkura Phase III studies.

  • Pooled data from SAkura open-label extension (OLE) studies support continued effect of ENSPRYNG reducing risk of relapse in the longer term

  • Ongoing data continues to show a favourable safety profile for ENSPRYNG

  • ENSPRYNG was recently approved by the U.S. Food and Drug Administration (FDA) for adults with anti-aquaporin-4 (AQP4) antibody positive NMOSD

Basel, 10 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new ENSPRYNG® (satralizumab) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MSVirtual2020, the 8th joint ACTRIMS-ECTRIMS meeting, in addition to longer-term efficacy data supporting the continued effect of ENSPRYNG on reducing the risk of NMOSD relapse, as well as its favourable benefit:risk profile.

“The data for ENSPRYNG at MSVirtual2020 are promising and

Read More

Optomi Significantly Reduces the Time and Expense of Hiring for Clients Seeking Technology Talent | News

ATLANTA, Sept. 9, 2020 /PRNewswire/ — Optomi, the technology talent brand of Optomi Professional Services, is known for significantly improving the interview-to-hire ratio for clients through a skill-set-focused approach to recruiting. Discovering culturally aligned candidates who possess the skills necessary to excel in their roles is a strength of Optomi’s.

A typical employer seeking to hire for a position will review 250 resumes and conduct 6-8 first interviews with 2-3 rounds afterward before making an offer to a single candidate. Optomi takes the burden from the hiring manager by vetting candidates so effectively that the firm averages an interview-to-hire ratio of 3:1 versus the industry norm of 6:1 (or worse).

“A time-consuming hiring process eats up hiring managers’ bandwidth and causes delays that can affect the entire organization. Our highly-effective skill-set approach to recruiting talent coupled with our proven processes streamline the hiring and greatly improve the chances that

Read More